|Bid||0.00 x 900|
|Ask||0.00 x 1300|
|Day's Range||65.78 - 68.84|
|52 Week Range||37.06 - 71.01|
|Beta (3Y Monthly)||1.43|
|PE Ratio (TTM)||30.54|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.13|
New regulation could force drug companies to disclose their prices on TV ads. Yahoo Finance's Seana Smith, Zack Guzman and Sibile Marcellus discuss.
GAITHERSBURG, Md., Nov. 06, 2018 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the.
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -11.29% and -7.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of 41 cents. Earnings, adjusted for one-time gains and costs, were 55 cents per share. The results missed Wall Street ...
Q3 2018 performance in line with guidanceRevises full year 2018 financial forecast to reflect anticipated strong full year organic business performance, expected at the higher.
The Gaithersburg biotech filed a lawsuit against a generic drugmaker for patent infringement, after it applied to market a generic version of Narcan Nasal Spray, which reverses the effects of opioid overdose.
Based on Emergent BioSolutions Inc’s (NYSE:EBS) earnings update in June 2018, the consensus outlook from analysts appear fairly confident, as a 21% increase in profits is expected in the upcoming Read More...
On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.
Emergent BioSolutions is the IBD Stock Of The Day as the company's shares sidestepped a biotech sell-off. On the stock market today, Emergent Bio stock jumped 3.1% to close at 60.33.
This article is intended for those of you who are at the beginning of your investing journey and want to learn about the link between company’s fundamentals and stock market Read More...
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
New initiatives make free doses and educational materials available to thousands of public libraries & YMCAs in the U.S. GAITHERSBURG, Md., Oct. 24, 2018 -- Emergent.
Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.
GAITHERSBURG, Md., Oct. 15, 2018 -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN®.
GAITHERSBURG, Md., Oct. 11, 2018 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the.
"We are now in the next phase of this opioid crisis, where the majority of deaths arise from fentanyl.”
The following is a collection of this week’s deal closings for transactions involving private-equity firms and portfolio companies.
Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.